Camurus’ Nomination Committee appointed for the Annual General Meeting 2019
Lund — 16 October 2018 — According to the instruction for the Nomination Committee in Camurus AB adopted at Camurus’ annual general meeting (AGM) on 3 May 2016, the Nomination Committee shall be composed of representatives of the three largest shareholders in terms of voting rights as of 31 August, along with the Chairman of the Board of Directors. Camurus today announced that the Nomination Committee for the AGM 2019 consists of the following persons, together representing approximately 60 percent of the total number of shares and votes in the company based on the last known shareholder information:
- Per Sandberg, appointed by Sandberg Development AB,
- Max Mitteregger, appointed by Gladiator,
- Arne Lööw, Fjärde AP-fonden, and
- Per Olof Wallström, Chairman of the Board
The Nomination Committee’s proposals will be presented in the Notice to the AGM 2019 and on Camurus’ web site, www.camurus.com.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 8 February 2019, to ensure that the proposals can be considered by the Nomination Committee.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20
The information was submitted for publication at 07.00 a.m. CET on 16 October 2018.